Cargando…

Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer

Proteomic techniques are currently used to understand the biology of different human diseases, including studies of the cell signaling pathways implicated in cancer progression, which is important in knowing the roles of different proteins in tumor development. Due to its poor prognosis, proteomic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marrugal, Ángela, Ojeda, Laura, Paz-Ares, Luis, Molina-Pinelo, Sonia, Ferrer, Irene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944034/ https://www.ncbi.nlm.nih.gov/pubmed/27445423 http://dx.doi.org/10.1155/2016/2138627

Ejemplares similares

Corrigendum to “Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer”
por: Marrugal, Ángela, et al.
Publicado: (2018)

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry
por: Marrugal, Ángela, et al.
Publicado: (2019)

Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma
por: Marrugal, Ángela, et al.
Publicado: (2021)

The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2018)

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy
por: Marrugal, Ángela, et al.
Publicado: (2023)

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
por: Quintanal-Villalonga, A., et al.
Publicado: (2016)

Corrigendum to “Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications”
por: Quintanal-Villalonga, A., et al.
Publicado: (2018)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2018)

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
por: Ferrer, Irene, et al.
Publicado: (2018)

Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer
por: Molina-Pinelo, Sonia, et al.
Publicado: (2016)

Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer
por: Verdugo-Sivianes, Eva M., et al.
Publicado: (2017)

Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer
por: Boyero, Laura, et al.
Publicado: (2023)

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers
por: Usó, Marta, et al.
Publicado: (2016)

MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer
por: Molina-Pinelo, Sonia, et al.
Publicado: (2014)

Landscape of tumor and immune system cells-derived exosomes in lung cancer: mediators of antitumor immunity regulation
por: Castillo-Peña, Alejandro, et al.
Publicado: (2023)

The Roles of Imprinted SLC22A18 and SLC22A18AS Gene Overexpression Caused by Promoter CpG Island Hypomethylation as Diagnostic and Prognostic Biomarkers for Non-Small Cell Lung Cancer Patients
por: Noguera-Uclés, José Francisco, et al.
Publicado: (2020)

Identification of Oxidative Stress Related Proteins as Biomarkers for Lung Cancer and Chronic Obstructive Pulmonary Disease in Bronchoalveolar Lavage
por: Pastor, Maria Dolores, et al.
Publicado: (2013)

Association between the miRNA Signatures in Plasma and Bronchoalveolar Fluid in Respiratory Pathologies
por: Molina-Pinelo, Sonia, et al.
Publicado: (2012)

Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer
por: Estevez-Garcia, Purificacion, et al.
Publicado: (2015)

Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
por: Boyero, Laura, et al.
Publicado: (2020)

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome
por: Estevez-Garcia, Purificacion, et al.
Publicado: (2012)

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
por: Kempf, Emmanuelle, et al.
Publicado: (2016)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
por: Alonso-García, Miriam, et al.
Publicado: (2022)

Enhanced Cytotoxic Activity of Mitochondrial Mechanical Effectors in Human Lung Carcinoma H520 Cells: Pharmaceutical Implications for Cancer Therapy
por: González Rubio, Sergio, et al.
Publicado: (2018)

Foreword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

Summary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer
por: Molina-Pinelo, Sonia, et al.
Publicado: (2014)

A Proteomic Approach to the Identification of Lung Cancer Markers
por: Hanash, Samir, et al.
Publicado: (2001)

Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy
por: García-Heredia, José M., et al.
Publicado: (2016)

Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain
por: Manso, Luis, et al.
Publicado: (2020)

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
por: Paz-Ares, Luis, et al.
Publicado: (2010)

Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
por: Zugazagoitia, Jon, et al.
Publicado: (2017)

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
por: Ortega-Franco, A., et al.
Publicado: (2021)

Bronchoalveolar Lavage Proteomics in Patients with Suspected Lung Cancer
por: Carvalho, Ana Sofia, et al.
Publicado: (2017)

Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
por: Sánchez-Gastaldo, Amparo, et al.
Publicado: (2021)

Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy
por: Ramos-Paradas, Javier, et al.
Publicado: (2022)

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer
por: Moutafi, Myrto K, et al.
Publicado: (2022)

Quantitative proteomics in lung cancer
por: Cheung, Chantal Hoi Yin, et al.
Publicado: (2017)

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
por: Romaniello, Donatella, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9sfuvf084k8va0o2rtu8hj099d